Clinical trial Recruiting at 2 sites Observational Ages 6 to 18

Genetic links to myopia in children and adolescents

Official title: Genetic Variants and Their Association With Myopia Risk, Progression, and Optimal Interventions in Children

Run by Beijing Visionly Plus Eye Hospital · NCT07030153 · Data updated 2026-11-12

The team will test whether specific gene variants influence myopia risk and progression in children and adolescents and whether those genes change how well treatments like low‑dose atropine drops, orthokeratology lenses, specialty glasses, or more outdoor time work.

More Myopia trials

Quick facts

Study typeObservational
Ages6 Years to 18 Years
SexAll
Enrollment1000 (estimated)
SponsorBeijing Visionly Plus Eye Hospital
Academic / other
Locations2 sites (Beijing and 1 other locations)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedAugust 31, 2028
Study endsDecember 31, 2028
Registry record updatedJune 22, 2025
Trial IDNCT07030153 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adolescents aged 6–18 with any spherical equivalent refraction whose parents or guardians consent to genetic testing and who do not have suspected genetic syndromes, other eye diseases, or prior refractive surgery are ideal candidates.

Probably not a fit

Patients with known genetic syndromes affecting the eye, other ocular diseases (for example glaucoma, cataracts, or retinal abnormalities), prior refractive surgery, or adults outside the 6–18 age range are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will collect DNA via oral swab from participants aged 6–18 and analyze myopia-related gene variants. Researchers will link genetic data to clinical measures such as spherical equivalent refraction and axial length change, and they will record participants' use of common myopia control measures (low-dose atropine, orthokeratology, specialized lenses, and time outdoors). The team will model gene-by-treatment interactions to see whether genetic profiles modify treatment response and disease progression. Finally, investigators will develop a genetic risk score intended to support personalized myopia prevention and treatment strategies.

Why it matters

Potential benefit: If successful, this work could allow prediction of which children are at higher risk and help match them to the most effective preventive or treatment strategies.

How similar studies have gone: Previous research has identified genetic variants and polygenic risk scores associated with myopia risk, but evidence for consistent gene-by-treatment interactions and routine clinical use remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 6-18 years.
* Any Spherical equivalent refraction (SER)
* Parental consent for genetic testing.

Exclusion Criteria:

* Suspected genetic syndromes (e.g., Stickler, Marfan).
* Other eye diseases (e.g., glaucoma, cataracts, retinal abnormalities, strabismus).
* Prior refractive surgery

Where it's running

  • Beijing New Vision Eye Hospital
    Beijing, China
    Recruiting
  • Beijing Visionly Plus Eye Hospital
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.